Insilico and Bora Pharmaceuticals forge strategic AI-driven drug discovery alliance

Insilico Medicine has entered a partnership with Bora Pharmaceuticals to integrate AI-driven drug discovery platforms into the contract manufacturer's production processes. The agreement, valued at up to $2.5 billion, aims to accelerate the development and commercialization of new therapeutics by leveraging Insilico's proprietary generative artificial intelligence tools.